Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 449.825 USD -0.12% Market Closed
Market Cap: 115.8B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

24
Current
19.4
Median
4.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
24
=
Enterprise Value
108.2B USD
/
EBITDA
4.5B USD
All Countries
Close
EBITDA Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 17.2
24
38%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.4
63%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -225.3 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
81.4
2-Years Forward
EV/EBITDA
19.3
3-Years Forward
EV/EBITDA
17.3

See Also

Discover More